Plasma exchange for @entity8 and XXXX rapidly progressive @entity631 : a meta-analysis.

@entity1 @entity8 @entity1011 @entity3762 @entity631 @entity204 @entity454
BACKGROUND: Plasma exchange may be effective adjunctive treatment for @entity8 . We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for @entity8 . STUDY DESIGN: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. SETTING _ POPULATION: Adults with @entity8 or rapidly progressive @entity631 . SELECTION CRITERIA FOR STUDIES: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult @entity1 with either @entity8 or @entity3762 rapidly progressive @entity631 . INTERVENTION: Adjuvant plasma exchange. OUTCOME: Composite of @entity454 or @entity204 . RESULTS: We identified 9 trials including 387 @entity1 . In a fixed-effects model, the pooled RR for @entity454 or @entity204 was 0.80 for @entity1 treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I(2) = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum @entity1011 values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for @entity454 was 0.64 (95% CI, 0.47-0.88; P = 0.006), whereas the RR for @entity204 alone was 1.01 (95% CI, 0.71-1.4; P = 0.9). LIMITATIONS: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of @entity454 or @entity204 . CONCLUSIONS: Plasma exchange may decrease the composite end point of @entity454 or @entity204 in @entity1 with @entity8 . Additional trials are required given the limited data available.
